The US market with its headwinds related to increased competitive intensity, pricing pressures and high regulations, has not remained as lucrative as it was five to six years ago. Companies have naturally turned towards tending to the domestic market - the other large piece of their business. The Covid pandemic also made companies aware of gaps and non-core segments in their portfolios.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kioHx5b
via IFTTT
0 comments:
Post a Comment